59 results about "Ige binding" patented technology

The invention discloses a method for detecting mite allergen specific antibody in blood serum. The method comprises the following steps of: coupling mite allergen with surface carboxyl modified magnetic microspheres to prepare immunomagnetic microspheres; and mixing and incubating the blood serum to be detected and the immunomagnetic microspheres in holes of an elisa (enzyme-linked immunosorbent assay) plate to combine mite allergen with mite allergen specificity IgE in the blood serum, and detecting by adopting an enzyme-linked immunosorbent method after the elisa plate is washed. In the method disclosed by the invention, a mite allergen is directly coupled onto the surfaces of magnetic microspheres, thus all the impurities except the mite allergen specific antibody in the blood serum can be conveniently removed; and targeted mite allergen specificity antibody detection is carried out, detection time is shortened, and sensitivity, specificity and accuracy of detection are improved. The mite allergen immunomagnetic microspheres prepared by the invention can be used in standard automatic detection to improve detection efficiency.

The invention discloses a method for detecting allergen-specific antibodies in serum. The method comprises the following steps: coupling anti-human IgE antibodies with carboxyl surface modified magnetic microballoons to obtain immunomagnetic microspheres; incubating the immunomagnetic microspheres with serum to be measured so as to enable the immunomagnetic microspheres to bind to IgE in the serum to be measured; carrying out magnetic separation to obtain immunomagnetic microsphere-IgE conjugates, dissolving deposition of the magnetic separation in a buffer solution, adding the mixed solution into apertures of an enzyme label plate which is coated with allergen, and carrying out detection by the ELISA adsorption method after incubation and plate washing. According to the invention, magnetic microballoons are coupled with anti-human IgE antibodies to prepare immunomagnetic microspheres which are mixed with serum to be measured for incubation and are bond to all the IgE in serum; the immunomagnetic microspheres are enriched and IgE is separated; the ELISA adsorption method is employed to detect whether there is specific IgE bond to allergen in serum. The method provided in the invention enables all the IgE to be separated from serum through immunomagnetic microspheres, impurities to be removed, and sensitivity, specificity and accuracy of ELISA adsorption detection to be improved.

Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are non-naturally occurring mutants of naturally-occurring allergens. The overall alpha-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.

It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.

It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than-within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

The invention discloses the main sensitization protein of humulus pollen which can be separated and obtained from the humulus pollen and combined with over 89 percent of serological specificity IgE of patients allergic to humulus pollen. The apparent molecular weight of the protein measured by SDS-PAGE is about 12kDa, the isoelectric point is 4.7 and the N-terminal sequence is NH4<+>-MDNPFENGMKA-COO<->. The separation and purification of the protein lay the foundation for realizing the standization of the allergenic preparations of the protein.

Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall alpha-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.

The invention relates to the biotechnology field, and more specifically, the invention discloses a human monoclonal antibody against IgE, a preparation method and a purpose thereof. According to the invention, a natural human phage antibody library of large capacity is constructed;; a human antibody 2E19 strain against IgE is obtained through screening from the library; an amino acid sequence of a heavy chain variable region is expressed as SEQ ID NO: 6; and the amino acid sequence of a light chain variable region is expressed as SEQ ID NO: 8. Besides, the invention also discloses the preparation method of the antibody 2E19, as well as a nucleotide sequence for encoding the antibody 2E19 and an expression vector and a host cell comprising the nucleotide sequence. The antibody 2E19 of the invention has a higher antibody affinity, so as to be able to obviously inhibit degranulation caused by the combination of IgE and FC epsilon RI on a cell surface, and the antibody 2E19 does not combine with the IgE combined with the FC epsilon RI on the cell surface. The antibody 2E19 of the invention could be used for the preparation of a medicine for treating hypersensitivity diseases, especially for treating allergic asthma.

The present invention provides a method to produce variant recombinant mite Group 1 proteins with properties suitable for accelerated, specific immunotherapy. The variants of the present invention have greatly reduced IgE binding activity, but little or no loss in the ability to stimulate T cells in allergic individuals. The present invention also relates to a variant mite Group 1 protein obtained by such a method, and the use of such a variant mite Group 1 protein to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.

The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.

The invention provides a coding gene of scylla paramamosain allergenic protein and an application thereof. The coding gene of the allergenic protein is composed of a nucleotide sequence shown in SEQ ID NO: 1. The invention also discloses an expression vector and a recombinant strain containing the gene, a method for preparing the allergenic protein and the application of the allergenic protein. The coding gene of the scylla paramamosain allergenic protein is cloned into a prokaryotic expression vector, recombinant expression plasmid is constructed, and transferred into host bacteria and inducing expression is carried out; the scylla paramamosain allergenic protein rScy p 9 can be obtained, the IgE binding capacity of the scylla paramamosain allergenic protein rScy p 9 and serum of a crustacean allergic patient is measured, a reference basis can be provided for clinical diagnosis of allergic symptoms and detailed screening of allergens, and prevention, control and treatment of allergicdiseases of the Scy p 9 are timely and accurate.

The invention provides a monoclonal antibody of the main sensitization protein of humulus pollen, which is obtained by taking the main sensitization protein of the humulus pollen as an immunogen. The main sensitization protein of the humulus pollen can be separated and obtained from the humulus pollen and be combined with over 89 percent of serological specificity IgE of patients allergic to the humulus pollen. The apparent molecular weight of the protein measued by SDS-PAGE is about 12kDa, the isoelectric point is 4.7 and the N-terminal sequence is NH4<+>-MDNPFENGMKA-COO<->. The monoclonal antibody can be used for the quantitative marking of the main sensitization protein in the allergenic preparations of the humulus pollen.

The present invention relates generally to reagents useful in the immunotherapeutic or immunoprophylactic treatment of allergic diseases. More particularly, the present invention provides modified allergens exhibiting reduced IgE interactivity including reduced IgE production-stimulatory activity, while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions. The present invention further contemplates a method of immunomodulation of allergic diseases such as type I allergic disease conditions by the administration of modified allergens exhibiting reduced IgE interactivity while retaining T-cell antigenicity.

The present invention relates to a method for identifying allergenic proteins and peptides. More specifically, the present invention provides a method for identifying allergenic milk proteins and / or peptides comprising the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating mammal, preferably a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to mammalian milk,preferably cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide at least one mediator.

The invention provides a mutant of scylla paramamosain allergic protein Scy p 4 and application thereof, wherein the mutant is obtained by mutating the 70th site of an amino acid sequence of the scylla paramamosain allergic protein Scy p 4 into alanine, and the amino acid sequence of scylla paramamosain allergic protein Scy p 4 is shown in SEQ ID NO: 1. According to the mutant of the scylla paramamosain allergic protein Scy p 4, a wild type Scy p 4 gene is subjected to site-directed mutagenesis by means of overlap extension PCR, the mutated gene is recombined with an expression vector and thentransferred into host cells, and the mutant of the Scy p 4 gene with low allergenicity is successfully constructed; and compared with the wild type allergen, the mutant has reduced IgE binding activity, and the mutant can be used for immunotherapy or immunoprophylaxis, and can reduce side effects in immunotherapy and improve safety index of treatment.

The invention provides a novel humanized anti-IgE monoclonal antibody, which can be combined with IgE and can inhibit the anaphylactic reaction caused by combination of IgE with a receptor Fc EpsilonRI; higher stability is realized. The novel humanized anti-IgE monoclonal antibody provided by the invention can be used for treating allergic diseases, and is used for treating allergic asthma or urticaria.

Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are non-naturally occurring mutants of naturally-occurring allergens. The overall PROPORTIONAL -carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.

The invention relates to a method for performing high-solubility expression and purification on dermatophagoides pteronyssinus major allergen Der p 2 protein in Escherichia coli. According to the method, the Escherichia coli chaperonin trigger factor (TF) is used as a fusion tag to implement high-solubility expression of Der p 2 and obtain the optimized high-efficiency purification technique; and the purity of the sample obtained by the method is higher than 98%. The verification proves that the purified recombinant Der p 2 protein has a consistent secondary structure folding state with the naturally extracted Der p 2 protein and has the identical combination activity with specific IgE in the serum of the dermatophagoides-pteronyssinus-allergic patient. The fusion expression method used in the invention can implement soluble expression of the Der p 2 protein, has the advantages of cuttable fusion tag, high recombinant protein expression level and simple purification technique, is suitable for large-scale industrial production, and can maintain the natural activity of the product.

Disclosed is a method for identification of key amino acids in plant proteins critical in generating allergenic activity through mapping the epitope(s) harboring human IgE binding activity. The identified epitope (s) are then modified by amino acid substitution preferably by alanine substitution, for reduced or negative IgE-binding activity. A plant gene expression system comprising a DNA construct placed operably under the control of a promoter sequence that confers seed-specific expression is also disclosed for the expression of the modified proteins. The Brazil nut 2S sulfur-rich protein was exemplified. The method disclosed herein is particularly useful for the production of dietary proteins with improved nutritional quality and reduced or negative allergenicity for human and animal consumption through genetic engineering.

The invention relates to IgE antagonists, including monoclonal antibodies, and their use in ameliorating asthma and allergic diseases in offspring of mothers treated during pregnancy with such antagonists. The preferred IgE antagonists do not induce release of the mediators of allergy. One example of such IgE antagonists are anti-IgE antibodies which bind to secreted IgE, to membrane IgE on the surface of IgE-producing B cells, but not to IgE bound to the Fc∈RI on the surface of basophils or mast cells. Preferably, these antibodies also do not bind to IgE bound to Fc∈RII receptors. It is also preferable if these antibodies have human IgG1 or IgG3 constant regions, as well as further human portions, if desired.

The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv) that binds to a mammalian IgE at an epitope within the amino acid sequence VDGQKATNIFPYTAPGTK (SEQ ID NO:1) of canine IgE or at an epitope within the corresponding amino acid sequence of a different mammalian species; b) a linker peptide; and c) an amino acid sequence comprising an IgE high affinity receptor alpha chain, and methods of use thereof.

Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are non-naturally occurring mutants of naturally-occurring allergens. The overall PROPORTIONAL -carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.

The invention relates to a pharmaceutical composition for treatment of atopic dermatitis comprising a suitable IgE antagonist which does not induce release of the mediators of allergy; for example, anti-IgE antibodies which bind to secreted IgE, to membrane IgE on the surface of IgE-producing B cells, but not to IgE bound to the Fc epsilon RI on the surface of basophils or mast cells. Preferably, these antibodies also do not bind to IgE bound to Fc epsilon RII receptors. It is also preferable if these antibodies have human IgG1 or IgG3 constant regions, as well as further human portions, if desired. The pharmaceutical composition can be administered systemically or topically.

The invention discloses a processing method for a low-allergenic soybean powder, belonging to a traditional soybean product processing technology. The processing method comprises the following steps:(1) soaking selected soybeans, then wiping moisture from soaked soybeans with a gauze, and placing wiped soybeans into a vacuum refrigerator; (2) laying frozen soybeans onto the gauze, and placing thegauze into an ultrasonic hot-air dryer; (3) directly pulping dried soybeans, carrying out filtering with a filter screen, stewing obtained raw soybean milk in a stewing pot, carrying out continuous boiling, and adding alkaline protease; (4) conveying the soybean milk into a homogenizer for homogenization, and carrying out spray-drying; and (5) irradiating obtained soybean powder with a pulsed ultraviolet light for sterilization so as to obtain the low-allergenic soybean powder. According to the invention, by combination of soybean vacuum freezing with an ultrasonic hot-air drying technology and an ultraviolet pulse technology, various microorganisms in food and packaging are killed through instantaneous and high-intensity pulse light energy; immunoreactivity is reduced, and changing of aprotein structure and reduction of an IgE binding ability are promoted, so allergenicity of the soybeans is reduced; compared with traditional hot-air drying, ultrasonic hot-air drying needs shorter heating time, so allergenic substances in the soybeans are rapidly destroyed; and bacteria in the soybean powder grow more slowly than the bacteria in traditional soybean powder, so the shelf life of the soybean powder is prolonged.

The invention provides an anti-sFc [epsilon] RI [alpha] monoclonal antibody and application thereof. Specifically, the invention provides preparation and application of a hybridoma cell strain for generating an anti-sFc [epsilon] RI [alpha] monoclonal antibody. The anti-sFc [epsilon] RI [alpha] monoclonal antibody aims at a non-IgE binding site of sFc [epsilon] RI [alpha], and the combination of the anti-sFc [epsilon] RI [alpha] monoclonal antibody and the non-IgE binding site does not influence the combination of sFc [epsilon] RI [alpha] and IgE. The antibody can be combined with a sFc [epsilon] RI [alpha] antigen with high specificity, and has high affinity, good specificity and high antibody titer (the combination rate of the antibody diluted by 1: 50 times and sFc [epsilon] RI [alpha]reaches 96.7%). The antibody can simply, conveniently, quickly and specifically carry out accurate analysis and detection on trace sFc [epsilon] RI [alpha], and lays a good foundation for researchingthe effect of the protein on various diseases.

The invention relates to a human immune globulin epsilon heavy chain constant region (hIgE Fc) fragment protein and a preparation method and an application thereof. The human immune globulin epsilon heavy chain constant region (hIgE Fc) fragment protein is capable of combining an IgE binding site on Fc epsilon RI molecule. The human immune globulin epsilon heavy chain constant region (hIgE Fc) fragment protein can be used for allergy diseases, such as allergy asthma and rhinitis.

The invention provides recombinant fish roes and a preparation method thereof. The recombinant fish roes are prepared by the following steps: (1), preparing a reaction product stock solution; (2), preparing mixed paste of fresh fish roes and egg liquid; (3), carrying out deodorization by using ozone of which the concentration is 1.8mg / L; (4), preparing a starch solution; (5), preparing an edible gum solution; (6), adding water, and carrying out uniform mixing; (7), carrying out soaking in a calcium chloride solution for 10 minutes; and (8), carrying out soaking in gallotannic acid for 20 minutes, fishing the soaked fish roes out, and carrying out thorough draining so as to obtain the recombinant fish roes. The recombinant fish roes provided by the invention have the following advantages: (1), the recombinant fish roes are low in allergen IgE binding activity; (2), the recombinant fish roes are uniform in granules, small in fishy smell, rich in nutrition, and unique in flavor; and (3), the preparation method of the recombinant fish roes is simple in processes, and relatively low in cost.